A Study for Older Adults With Acute Lymphoblastic Leukaemia
Status:
Active, not recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
The NCRI Adult ALL sub-group propose to collaborate with the Dutch/Belgian group HOVON to
carry out a prospective, non randomised multi-arm study (including a choice of regimen
intensity) to investigate the safety, tolerability and feasibility of a standardised therapy
protocol for patients ≥ 60 years old with de novo ALL. The overall aim is define a basic
standard of care upon which trials of novel therapies will be based in future. The design of
the study will enable collection of a comprehensive dataset regarding the clinical outcome,
Complete Response Rate (CR) and Minimal Residual Disease (MRD) response rates in a previously
completely uncharacterised population, thus providing the essential platform for designing
future randomised advanced phase studies in which new therapeutic approaches and novel
therapies can be prospectively investigated.
Phase:
Phase 2
Details
Lead Sponsor:
University College, London
Collaborators:
Cancer Research UK Stichting Hemato-Oncologie voor Volwassenen Nederland